See analyst estimates and all valuation multiples for Biopharmaceuticals
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $990B | 16.1x | 36.2x | |
| $524B | 5.6x | 14.8x | |
| $469B | 7.8x | 18.3x | |
| $333B | 4.4x | 11.1x | |
| $307B | 5.3x | 15.2x | |
| $272B | 4.2x | 9.4x | |
| $267B | 4.8x | 11.7x | |
| $225B | 6.2x | 12.4x | |
| $207B | n/a | n/a | |
| $189B | 3.0x | 7.6x | |
| $173B | 5.9x | 11.2x | |
| $132B | 2.8x | 7.6x | |
| $128B | n/a | n/a | |
| $113B | 2.7x | 7.9x | |
| $103B | 8.7x | 20.8x | |
| $82.2B | 10.4x | 20.5x | |
| $72.1B | 1.4x | 6.5x | |
| $69.6B | 2.4x | 9.0x | |
| $67.0B | 2.7x | 9.6x | |
| $66.4B | 4.2x | 12.6x | |
| $59.3B | 6.3x | 14.4x | |
| $51.1B | n/a | n/a | |
| $51.1B | 11.1x | 36.9x | |
| $51.0B | 5.5x | 18.8x | |
| $45.0B | n/a | n/a | |
| $43.5B | n/a | n/a | |
| $41.2B | n/a | n/a | |
| $33.9B | n/a | n/a | |
| $29.1B | n/a | n/a | |
| $28.6B | n/a | n/a | |
| $27.0B | n/a | n/a | |
| $26.9B | 13.3x | 35.6x | |
| $25.7B | 1.8x | 6.2x | |
| $25.3B | 2.0x | 8.8x | |
| $24.1B | 8.1x | 8.4x | |
| $22.0B | 62.0x | 23879.5x | |
| $22.0B | n/a | n/a | |
| $19.3B | 10.7x | 80.6x | |
| $18.9B | 130.6x | 249.3x | |
| $16.7B | 1.9x | 8.0x | |
| $15.8B | n/a | n/a | |
| $14.7B | 3.2x | 11.8x | |
| $14.2B | 10.2x | 31.1x | |
| $14.1B | 4.7x | 12.7x | |
| $13.5B | 4.6x | 11.9x | |
| $13.4B | 4.8x | 20.2x | |
| $13.0B | 28.6x | -919.8x | |
| $12.9B | 46.8x | -275.3x | |
| $12.9B | 2.2x | 12.6x | |
| $12.4B | 3.9x | 16.0x | |
| $12.2B | 2.1x | 14.3x | |
| $11.7B | 0.3x | 5.2x | |
| $11.4B | 2.7x | 7.1x | |
| $11.2B | 3.0x | 12.1x | |
| $11.1B | 3.6x | 9.0x | |
| $10.8B | n/a | n/a | |
| $10.6B | 3.8x | 13.7x | |
| $10.5B | n/a | n/a | |
| $10.4B | 12.8x | 40.6x | |
| $10.1B | 3.7x | 14.4x | |
| $10.1B | 3.1x | 7.4x | |
| $10.0B | 1.6x | 5.2x | |
| $9.9B | 1.6x | 12.6x | |
| $9.8B | n/a | n/a | |
| $9.8B | 2.5x | 9.9x | |
| $9.7B | n/a | n/a | |
| $9.5B | 7.3x | 11.1x | |
| $8.8B | 3.6x | 5.6x | |
| $8.0B | 1.6x | 12.6x | |
| $7.9B | n/a | n/a | |
| $7.8B | n/a | n/a | |
| $7.6B | 2.1x | 10.1x | |
| $7.2B | 4.6x | 23.2x | |
| $7.1B | 2.3x | 10.2x | |
| $7.0B | 3.7x | 18.1x | |
| $6.8B | n/a | n/a | |
| $6.7B | 17.6x | -423.3x | |
| $6.5B | 2.8x | 10.3x | |
| $6.3B | 5.5x | 18.6x | |
| $6.3B | 2.1x | 9.3x | |
| $6.3B | 1.5x | 8.3x | |
| $6.0B | 1.8x | 7.1x | |
| $5.9B | 1.9x | 7.8x | |
| $5.8B | 3.9x | 45.9x | |
| $5.8B | 15.6x | 23.4x | |
| $5.7B | n/a | -21.5x | |
| $5.7B | 84.9x | -690.1x | |
| $5.6B | 3.4x | 18.5x | |
| $5.5B | n/a | n/a | |
| $5.4B | 2.8x | 11.0x | |
| $5.1B | n/a | n/a | |
| $5.1B | 6.0x | 27.3x | |
| $4.9B | n/a | n/a | |
| $4.9B | 1.8x | 4.8x | |
| $4.8B | 8.3x | 24.6x | |
| $4.7B | n/a | n/a | |
| $4.7B | 4.9x | 13.1x | |
| $4.6B | n/a | n/a | |
| $4.5B | n/a | -28.3x | |
| $4.5B | 4044.7x | -15.7x | |
| $4.5B | 5.4x | 18.8x | |
| $4.4B | n/a | n/a | |
| $4.4B | 8.8x | 23.0x | |
| $4.4B | n/a | n/a | |
| $4.3B | n/a | n/a | |
| $4.1B | n/a | n/a | |
| $4.0B | n/a | -10.4x | |
| $4.0B | 3.9x | 17.9x | |
| $3.8B | n/a | n/a | |
| $3.8B | 129.8x | n/a | |
| $3.7B | 10.8x | -257.5x | |
| $3.7B | 2.2x | 10.9x | |
| $3.6B | n/a | n/a | |
| $3.5B | n/a | n/a | |
| $3.5B | n/a | n/a | |
| $3.4B | 5.0x | 16.3x | |
| $3.3B | n/a | n/a | |
| $3.3B | 6.9x | -259.0x | |
| $3.2B | 7.6x | -46.0x | |
| $3.1B | n/a | n/a | |
| $3.1B | 2.4x | 11.6x | |
| $3.0B | n/a | n/a | |
| $3.0B | n/a | -13.1x | |
| $3.0B | n/a | n/a | |
| $3.0B | 1.4x | 9.5x | |
| $2.9B | n/a | n/a | |
| $2.9B | n/a | n/a | |
| $2.8B | 4.4x | 30.8x | |
| $2.8B | n/a | -14.5x | |
| $2.8B | 6.9x | 20.7x | |
| $2.7B | 4.3x | 10.2x | |
| $2.6B | 13.6x | 23.1x | |
| $2.6B | 4.1x | 13.8x | |
| $2.5B | n/a | n/a | |
| $2.5B | 20.3x | -130.0x | |
| $2.3B | 3.4x | 17.8x | |
| $2.3B | 2.8x | 13.5x | |
| $2.2B | n/a | -20.1x | |
| $2.2B | 3.6x | 14.2x | |
| $2.2B | 2.8x | 18.1x | |
| $2.2B | 2.6x | 9.9x | |
| $2.2B | 11.8x | 34.9x | |
| $2.2B | 8.2x | 75.0x | |
| $2.1B | 8.9x | -5.7x | |
| $2.1B | 5.7x | 16.5x | |
| $2.1B | n/a | n/a | |
| $2.1B | 6.8x | 17.6x | |
| $2.1B | 13.8x | n/a | |
| $2.0B | 40.9x | n/a | |
| $2.0B | 5.2x | 14.4x | |
| $2.0B | 2.6x | 4.4x | |
| $1.9B | n/a | -9.1x | |
| $1.9B | 8.4x | -70.1x | |
| $1.9B | n/a | n/a | |
| $1.8B | 48.3x | -8.9x | |
| $1.7B | n/a | n/a | |
| $1.7B | 3.9x | n/a | |
| $1.7B | 3.9x | 14.4x | |
| $1.7B | n/a | n/a | |
| $1.6B | n/a | -9.9x | |
| $1.6B | n/a | n/a | |
| $1.6B | 2.5x | 11.5x | |
| $1.6B | 6.0x | 23.9x | |
| $1.6B | 8.4x | 27.1x | |
| $1.6B | 2.2x | 6.1x | |
| $1.6B | n/a | n/a | |
| $1.6B | 0.7x | 4.2x | |
| $1.5B | n/a | n/a | |
| $1.5B | n/a | n/a | |
| $1.5B | n/a | n/a | |
| $1.5B | n/a | n/a | |
| $1.5B | n/a | n/a | |
| $1.4B | 6.3x | 25.9x | |
| $1.4B | n/a | n/a | |
| $1.4B | 14.3x | n/a | |
| $1.4B | n/a | n/a | |
| $1.3B | 4.8x | 27.9x | |
| $1.3B | 24.4x | 56.4x | |
| $1.3B | n/a | n/a | |
| $1.3B | 4.6x | 9.1x | |
| $1.3B | n/a | n/a | |
| $1.3B | 21.0x | n/a | |
| $1.3B | 0.6x | 6.3x | |
| $1.3B | n/a | n/a | |
| $1.3B | 8.2x | -4.7x | |
| $1.3B | 11.4x | -11.0x | |
| $1.3B | n/a | n/a | |
| $1.2B | n/a | n/a | |
| $1.2B | 37.6x | -11.4x | |
| $1.2B | n/a | n/a | |
| $1.2B | 2.0x | -194.9x | |
| $1.1B | n/a | n/a | |
| $1.1B | n/a | n/a | |
| $1.1B | n/a | n/a | |
| $1.1B | n/a | n/a | |
| $1.1B | n/a | n/a | |
| $1.0B | 398.0x | -7.1x | |
| $1.0B | n/a | n/a | |
| $1.0B | n/a | -9.7x | |
| $1.0B | n/a | n/a | |
| $999M | 3.3x | 7.3x | |
| $989M | n/a | -6.4x | |
| $988M | n/a | n/a | |
| $985M | 1.2x | 4.9x | |
| $979M | 3.0x | 36.0x | |
| $978M | 1.6x | -7.0x | |
| $969M | n/a | n/a | |
| $967M | 2.5x | 33.1x | |
| $967M | n/a | n/a | |
| $937M | n/a | n/a | |
| $920M | n/a | -7.2x | |
| $873M | n/a | n/a | |
| $864M | n/a | -6.0x | |
| $855M | n/a | n/a | |
| $853M | 68.0x | -2.6x | |
| $849M | n/a | n/a | |
| $826M | 25.0x | -12.8x | |
| $814M | 108397.6x | -7.2x | |
| $799M | n/a | n/a | |
| $794M | 6.2x | -4.8x | |
| $784M | n/a | n/a | |
| $779M | 1.3x | 6.4x | |
| $750M | 1.7x | 8.1x | |
| $746M | n/a | -5.2x | |
| $728M | 55.1x | n/a | |
| $727M | n/a | n/a | |
| $713M | n/a | n/a | |
| $691M | 2.5x | 11.6x | |
| $677M | 6.4x | 23.7x | |
| $666M | 77.0x | -5.3x | |
| $645M | 14.6x | 118.7x | |
| $620M | n/a | n/a | |
| $588M | n/a | -4.0x | |
| $577M | n/a | -3.9x | |
| $577M | 90.3x | -3.7x | |
| $563M | 3.6x | 20.9x | |
| $549M | n/a | n/a | |
| $536M | 27.6x | -171.6x | |
| $515M | n/a | n/a | |
| $510M | n/a | -2.4x | |
| $507M | 175.2x | -25.9x | |
| $503M | 20398.2x | n/a | |
| $496M | 37.6x | 73.9x | |
| $488M | 5.0x | 13.9x | |
| $463M | 3.2x | -3.5x | |
| $461M | n/a | n/a | |
| $456M | 10.0x | -6.1x | |
| $456M | 33.6x | -10.3x | |
| $451M | 7.0x | -21.1x | |
| $440M | n/a | n/a | |
| $440M | n/a | n/a | |
| $432M | n/a | n/a | |
| $421M | 2.2x | -3.6x | |
| $421M | 2.3x | 9.6x | |
| $421M | n/a | n/a | |
| $416M | 1.4x | 9.5x | |
| $412M | 77.9x | -12.8x | |
| $395M | 6.3x | 24.8x | |
| $386M | 1.2x | 4.4x | |
| $372M | 19.2x | -1295.0x | |
| $371M | 15.6x | -7.5x | |
| $356M | 1.2x | 9.8x | |
| $341M | 2.8x | 54.7x | |
| $339M | 11.2x | -1.7x | |
| $335M | 30462.2x | -3.7x | |
| $335M | n/a | n/a | |
| $331M | n/a | n/a | |
| $312M | n/a | n/a | |
| $311M | 1.3x | n/a | |
| $310M | 0.8x | 9.4x | |
| $305M | n/a | n/a | |
| $291M | 4.2x | 22.8x | |
| $262M | n/a | n/a | |
| $256M | 6.4x | -30.3x | |
| $255M | n/a | n/a | |
| $254M | 2.5x | 7.7x | |
| $254M | n/a | n/a | |
| $238M | n/a | n/a | |
| $238M | 10.3x | n/a | |
| $237M | 12.7x | 213.2x | |
| $235M | n/a | n/a | |
| $231M | 1.7x | 16.2x | |
| $226M | 2.7x | -10.1x | |
| $220M | n/a | -15.8x | |
| $218M | n/a | -29.2x | |
| $217M | 3.4x | 7.5x | |
| $216M | n/a | n/a | |
| $211M | 25.5x | -7.0x | |
| $211M | 10.6x | -5.0x | |
| $205M | n/a | n/a | |
| $201M | 4.7x | 22.9x | |
| $191M | n/a | n/a | |
| $188M | 2.9x | n/a | |
| $181M | n/a | n/a | |
| $178M | 6.1x | n/a | |
| $170M | 132.8x | -4.5x | |
| $169M | 46.4x | -3.8x | |
| $167M | 30.2x | -12.6x | |
| $162M | 4.8x | n/a | |
| $153M | n/a | n/a | |
| $145M | n/a | n/a | |
| $140M | 17.0x | -6.2x | |
| $138M | 2.5x | 118.1x | |
| $136M | n/a | n/a | |
| $136M | 5.9x | -3.7x | |
| $130M | n/a | n/a | |
| $128M | n/a | n/a | |
| $126M | 27.9x | -1.9x | |
| $125M | 9.2x | -3.1x | |
| $125M | n/a | n/a | |
| $124M | 21.6x | -10.3x | |
| $122M | n/a | n/a | |
| $120M | 2.0x | n/a | |
| $112M | 89.6x | -22.2x | |
| $112M | n/a | n/a | |
| $111M | n/a | -8.4x | |
| $108M | n/a | n/a | |
| $104M | n/a | n/a | |
| $102M | 1.5x | 9.1x | |
| $100M | n/a | n/a | |
| $97.9M | 6.6x | 22.7x | |
| $91.7M | n/a | n/a | |
| $90.5M | 28.8x | -1.6x | |
| $89.3M | 18.9x | -0.6x | |
| $84.9M | n/a | n/a | |
| $84.1M | n/a | n/a | |
| $83.6M | n/a | n/a | |
| $80.8M | n/a | -1.6x | |
| $79.5M | n/a | n/a | |
| $78.7M | n/a | n/a | |
| $77.8M | n/a | n/a | |
| $76.9M | n/a | n/a | |
| $75.1M | n/a | n/a | |
| $74.3M | n/a | n/a | |
| $73.4M | n/a | n/a | |
| $65.5M | n/a | n/a | |
| $64.4M | 7.4x | -8.5x | |
| $62.5M | n/a | n/a | |
| $59.4M | 556.0x | -9.6x | |
| $55.5M | n/a | n/a | |
| $53.8M | n/a | n/a | |
| $53.7M | n/a | n/a | |
| $52.4M | n/a | n/a | |
| $52.1M | 5.5x | 2.6x | |
| $50.3M | 0.2x | -1.0x | |
| $49.1M | n/a | n/a | |
| $48.0M | 35.6x | -58.2x | |
| $44.1M | n/a | n/a | |
| $43.5M | 9.1x | n/a | |
| $42.2M | n/a | -2.3x | |
| $41.5M | 5.9x | n/a | |
| $41.3M | 1.6x | 11.6x | |
| $39.8M | 10.4x | n/a | |
| $38.7M | 56.9x | -4.0x | |
| $35.4M | n/a | -7.7x | |
| $34.0M | n/a | n/a | |
| $33.2M | n/a | n/a | |
| $31.4M | 1.7x | 39.4x | |
| $30.6M | 8.0x | n/a | |
| $30.0M | n/a | n/a | |
| $29.6M | n/a | n/a | |
| $29.1M | n/a | n/a | |
| $28.8M | n/a | n/a | |
| $28.6M | 9.1x | -6.8x | |
| $28.4M | 0.4x | -0.1x | |
| $28.4M | n/a | n/a | |
| $27.9M | n/a | n/a | |
| $27.8M | 29.4x | n/a | |
| $27.2M | 3.7x | -1.4x | |
| $26.7M | n/a | n/a | |
| $26.7M | n/a | n/a | |
| $26.6M | n/a | n/a | |
| $25.7M | n/a | n/a | |
| $25.5M | 0.3x | -0.4x | |
| $23.7M | 38.3x | -2.3x | |
| $23.7M | n/a | n/a | |
| $23.5M | 11.3x | 100.2x | |
| $22.8M | n/a | -12.8x | |
| $20.0M | n/a | n/a | |
| $20.0M | n/a | n/a | |
| $19.4M | n/a | n/a | |
| $19.3M | n/a | n/a | |
| $19.2M | 18.5x | -5.2x | |
| $19.0M | n/a | n/a | |
| $18.9M | 2.8x | 7.9x | |
| $18.4M | n/a | n/a | |
| $18.2M | n/a | -4.4x | |
| $18.0M | n/a | n/a | |
| $17.8M | 13.9x | -6.6x | |
| $17.5M | n/a | -4.2x | |
| $17.3M | n/a | n/a | |
| $17.0M | 7.4x | -2.2x | |
| $16.0M | n/a | n/a | |
| $15.3M | n/a | n/a | |
| $15.1M | n/a | -5.3x | |
| $14.5M | n/a | n/a | |
| $14.3M | 2.7x | -5.2x | |
| $13.3M | 1.8x | -8.5x | |
| $13.3M | n/a | n/a | |
| $13.1M | n/a | n/a | |
| $13.1M | n/a | n/a | |
| $12.2M | n/a | n/a | |
| $12.2M | n/a | n/a | |
| $11.7M | n/a | n/a | |
| $11.7M | n/a | n/a | |
| $11.6M | n/a | n/a | |
| $11.3M | 153.9x | -5.4x | |
| $11.1M | 11.9x | -18.9x | |
| $10.8M | n/a | n/a | |
| $9.9M | n/a | -5.0x | |
| $9.9M | n/a | n/a | |
| $9.8M | 7.2x | -24.3x | |
| $9.6M | 3.0x | -3.6x | |
| $9.4M | 1.6x | -1.0x | |
| $9.3M | n/a | n/a | |
| $9.1M | n/a | n/a | |
| $9.0M | n/a | n/a | |
| $8.7M | n/a | n/a | |
| $8.6M | n/a | -2.5x | |
| $8.3M | n/a | n/a | |
| $8.0M | n/a | -2.1x | |
| $7.1M | n/a | n/a | |
| $7.0M | n/a | -1.3x | |
| $6.9M | 13.9x | n/a | |
| $6.8M | n/a | -7.5x | |
| $6.8M | n/a | n/a | |
| $6.1M | n/a | n/a | |
| $6.1M | n/a | n/a | |
| $6.1M | n/a | n/a | |
| $5.9M | 3.3x | -0.4x | |
| $5.2M | 6.5x | -0.4x | |
| $4.7M | 3.7x | -1.3x | |
| $4.7M | n/a | n/a | |
| $4.0M | n/a | -2.4x | |
| $3.9M | n/a | n/a | |
| $3.7M | 32.4x | -1.3x | |
| $3.7M | n/a | n/a | |
| $3.6M | 31.2x | -1.1x | |
| $3.4M | n/a | n/a | |
| $3.3M | n/a | n/a | |
| $3.2M | n/a | n/a | |
| $3.1M | n/a | n/a | |
| $3.0M | n/a | n/a | |
| $2.7M | n/a | n/a | |
| $2.7M | n/a | n/a | |
| $2.3M | n/a | n/a | |
| $2.1M | n/a | n/a | |
| $1.7M | n/a | n/a | |
| $1.6M | n/a | n/a | |
| $1.6M | 2.0x | -0.1x | |
| $1.3M | n/a | n/a | |
| $1.2M | n/a | n/a | |
| $1.2M | n/a | 0.2x | |
| $1.1M | n/a | n/a | |
| $0.5M | n/a | n/a | |
| $0.4M | n/a | n/a | |
| $0.3M | n/a | n/a | |
| $0.2M | n/a | n/a | |
| $0.1M | n/a | n/a | |
| -$0.1M | -0.2x | 0.0x | |
| -$0.2M | n/a | n/a | |
| -$0.3M | n/a | n/a | |
| -$0.4M | n/a | n/a | |
| -$0.7M | n/a | n/a | |
| -$1.4M | -0.3x | 0.1x | |
| -$4.6M | n/a | 0.4x | |
| -$6.0M | n/a | n/a | |
| -$6.4M | n/a | n/a | |
| -$34.1M | n/a | n/a | |
| -$85.5M | n/a | n/a | |
| -$115M | n/a | n/a | |
| -$1.5B | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Biopharmaceuticals